Market Executive Summary

The global market for Next Generation Cancer Diagnostics was estimated to be worth US$ 8826 million in 2024 and is forecast to a readjusted size of US$ 28510 million by 2031 with a CAGR of 18.5% during the forecast period 2025-2031.

North American market for Next Generation Cancer Diagnostics was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Next Generation Cancer Diagnostics was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Next Generation Cancer Diagnostics was valued at $ million in 2024 and will reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The global key companies of Next Generation Cancer Diagnostics include Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, etc. In 2024, the global five largest players hold a share approximately % in terms of revenue.

This report aims to provide a comprehensive presentation of the global market for Next Generation Cancer Diagnostics, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Next Generation Cancer Diagnostics by region & country, by Type, and by Application.

The Next Generation Cancer Diagnostics market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next Generation Cancer Diagnostics.

Global Next Generation Cancer Diagnostics Companies Covered

Cepheid, Koninklijke Philips N.V, F. Hoffmann-La Roche Ltd, Qiagen, Novartis AG, Abbott, Thermo Fisher Scientific, Opko Health, Myriad Genetics, Agilent Technologies, GE Healthcare, PerkinElmer, Genomic Health, Illumina, Hologic, Almac Group, Janssen Global Services, Sysmex Corporation

Global Next Generation Cancer Diagnostics Market, by Region

North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Next Generation Cancer Diagnostics Market, Segment by Type

Next Generation Sequencing

qPCR & Multiplexing

DNA Microarrays

Others

Global Next Generation Cancer Diagnostics Market, Segment by Application

Hospitals

Clinics

Others

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Next Generation Cancer Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Next Generation Cancer Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Next Generation Cancer Diagnostics in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Related Reports:

Global Personalized Cancer Medicine Market Size, Share, Growth Drivers, Opportunities and Forecast To 2030

Global AI for Cancer Diagnosis Market Report, History and Forecast 2018-2029